IDO1 and cancer: Although not fully characterized, novel IC molecules have been discovered, such as B- and T-lymphocyte attenuator (BTLA) [95], B7-H3 [96] and indolamine dioxygenase (IDO) [97] that are under investigation for their potential clinical use in cancer patients.